## Luca De Nicola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1692340/publications.pdf

Version: 2024-02-01

66343 106344 4,961 117 42 65 citations h-index g-index papers 120 120 120 5288 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	15-year-change of phenotype and prognosis in non-dialysis CKD patients referred to a nephrology clinic. International Urology and Nephrology, 2022, 54, 679-686.	1.4	1
2	New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: a multicohort observational study. CKJ: Clinical Kidney Journal, 2022, 15, 1120-1128.	2.9	10
3	Salt intake correlates with night systolic blood pressure in non-dialytic chronic kidney disease. Nephrology Dialysis Transplantation, 2022, 37, 1387-1389.	0.7	4
4	No additional benefit of prescribing a very low-protein diet in patients with advanced chronic kidney disease under regular nephrology care: a pragmatic, randomized, controlled trial. American Journal of Clinical Nutrition, 2022, 115, 1404-1417.	4.7	24
5	A new CHA2DS2VASC score integrated with estimated glomerular filtration rate, left ventricular hypertrophy, and pulse pressure is highly effective in predicting adverse cardiovascular outcome in chronic kidney disease. European Journal of Preventive Cardiology, 2022, , .	1.8	O
6	Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial. Journal of the American Society of Nephrology: JASN, 2022, 33, 1569-1580.	6.1	65
7	Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?. Journal of Nephrology, 2022, , .	2.0	5
8	Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers. International Journal of Molecular Sciences, 2022, 23, 6378.	4.1	5
9	Are all erythropoiesis-stimulating agents created equal?. Nephrology Dialysis Transplantation, 2021, 36, 1369-1377.	0.7	13
10	Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 267-274.	0.7	13
11	Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects. Diagnostics, 2021, 11, 290.	2.6	16
12	Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study. Journal of Clinical Medicine, 2021, 10, 1322.	2.4	2
13	Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care. Nutrients, 2021, 13, 942.	4.1	11
14	Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovascular Diabetology, 2021, 20, 145.	6.8	91
15	Smoking habit as a risk amplifier in chronic kidney disease patients. Scientific Reports, 2021, 11, 14778.	3.3	10
16	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European Heart Journal, 2021, 42, 4891-4901.	2.2	80
17	Renal and metabolic effects of SGLT-2i and DPP-4i according to basal estimated glomerular filtration rate: Analysis from GIOIA, an observational prospective study. Diabetes Research and Clinical Practice, 2021, 178, 108990.	2.8	O
18	Anemia: A Connection Between Heart Failure and Kidney Failure. Cardiology Clinics, 2021, 39, 319-333.	2.2	3

#	Article	IF	Citations
19	Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease. Expert Opinion on Investigational Drugs, 2021, 30, 253-262.	4.1	10
20	Volume-Independent Sodium Toxicity in Peritoneal Dialysis: New Insights from Bench to Bed. International Journal of Molecular Sciences, 2021, 22, 12804.	4.1	1
21	Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics. Nephrology Dialysis Transplantation, 2020, 35, 138-147.	0.7	32
22	Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function― Journal of Nephrology, 2020, 33, 9-35.	2.0	73
23	Sex Differences in the Progression of CKD Among Older Patients: Pooled Analysis of 4 Cohort Studies. American Journal of Kidney Diseases, 2020, 75, 30-38.	1.9	46
24	Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer antiâ€hyperglycaemic drug matters?. Diabetes, Obesity and Metabolism, 2020, 22, 149-157.	4.4	21
25	Costâ€analysis of persistent hyperkalaemia in nonâ€dialysis chronic kidney disease patients under nephrology care in Italy. International Journal of Clinical Practice, 2020, 74, e13475.	1.7	5
26	Sodium toxicity in peritoneal dialysis: mechanisms and "solutions― Journal of Nephrology, 2020, 33, 59-68.	2.0	9
27	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 2925-2936.	6.1	82
28	Nephroprotection by SGLT2 Inhibition: Back to the Future?. Journal of Clinical Medicine, 2020, 9, 2243.	2.4	23
29	Indications for renal biopsy in patients with diabetes. Joint position statement of the Italian Society of Nephrology and the Italian Diabetes Society. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2123-2132.	2.6	9
30	Predictive effect of salt intake on patient and kidney survival in non-dialysis CKD: competing risk analysis in older versus younger patients under nephrology care. Nephrology Dialysis Transplantation, 2020, 36, 2232-2240.	0.7	7
31	The Role of Prognostic and Predictive Biomarkers for Assessing Cardiovascular Risk in Chronic Kidney Disease Patients. BioMed Research International, 2020, 2020, 1-13.	1.9	26
32	Highlights from the 60th national meeting of the Italian Society of Nephrology: celebrating the role of the nephrologist. Journal of Nephrology, 2020, 33, 1139-1142.	2.0	0
33	Precision Nephrology Is a Non-Negligible State of Mind in Clinical Research: Remember the Past to Face the Future. Nephron, 2020, 144, 463-478.	1.8	16
34	Area Deprivation and Risk of Death and CKD Progression: Long-Term Cohort Study in Patients under Unrestricted Nephrology Care. Nephron, 2020, 144, 488-497.	1.8	6
35	Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney. Cardiovascular Diabetology, 2020, 19, 35.	6.8	24
36	Sodium Intake and Chronic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 4744.	4.1	60

#	Article	IF	Citations
37	Sodium removal by peritoneal dialysis: a systematic review and meta-analysis. Journal of Nephrology, 2019, 32, 231-239.	2.0	30
38	Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report. Medicina (Lithuania), 2019, 55, 462.	2.0	10
39	Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal functionâ€.  Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1127-1150.	2.6	85
40	Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics. Journal of Nephrology, 2019, 32, 429-435.	2.0	5
41	SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Medicina (Lithuania), 2019, 55, 268.	2.0	47
42	Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology, Journal of Nephrology, 2019, 32, 499-516.	2.0	63
43	Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2019, 21, 1790-1800.	4.4	28
44	Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale. Frontiers in Cell and Developmental Biology, 2019, 7, 314.	3.7	62
45	Incremental dialysis in ESRD: systematic review and meta-analysis. Journal of Nephrology, 2019, 32, 823-836.	2.0	77
46	Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 233-240.	4.5	39
47	Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies. Nephrology Dialysis Transplantation, 2018, 33, 1942-1949.	0.7	74
48	Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe. Kidney International, 2018, 93, 1432-1441.	5.2	36
49	Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion. Endocrine, 2018, 59, 242-259.	2.3	15
50	Effect of post-nephrectomy acute kidney injury on renal outcome: a retrospective long-term study. World Journal of Urology, 2018, 36, 59-63.	2.2	11
51	Short-term blood pressure variability in nondialysis chronic kidney disease patients. Journal of Hypertension, 2018, 36, 2398-2405.	0.5	26
52	Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care. Journal of Clinical Medicine, 2018, 7, 499.	2.4	26
53	Dietary Salt Restriction in Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials. Nutrients, 2018, 10, 732.	4.1	107
54	Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. PLoS ONE, 2018, 13, e0202417.	2.5	11

#	Article	IF	Citations
55	Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice. Journal of Nephrology, 2018, 31, 653-664.	2.0	35
56	A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney International, 2017, 91, 1224-1235.	5.2	210
57	Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients. Clinical Drug Investigation, 2017, 37, 965-973.	2.2	7
58	The Importance of Ambulatory and Home Monitoring Blood Pressure in Resistant Hypertension Associated with Chronic Kidney Disease., 2017,, 39-58.		0
59	Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology. Journal of Nephrology, 2017, 30, 159-170.	2.0	19
60	Epidemiology of low-proteinuric chronic kidney disease in renal clinics. PLoS ONE, 2017, 12, e0172241.	2.5	26
61	Retarding Chronic Kidney Disease (CKD) Progression: A Practical Nutritional Approach for Non-Dialysis CKD. Nephrology @ Point of Care, 2016, 2, pocj.5000207.	0.2	6
62	Prediabetes as a Precursor to Diabetic Kidney Disease. American Journal of Kidney Diseases, 2016, 67, 817-819.	1.9	13
63	Worldwide growing epidemic of CKD: fact or fiction?. Kidney International, 2016, 90, 482-484.	5.2	24
64	Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8Âyears follow up study. Cardiovascular Diabetology, 2016, 15, 147.	6.8	6
65	Low-protein diets for chronic kidney disease patients: the Italian experience. BMC Nephrology, 2016, 17, 77.	1.8	76
66	Association of Body Mass Index with Clinical Outcomes in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta-Analysis. CardioRenal Medicine, 2016, 6, 37-49.	1.9	83
67	Chronic kidney disease prevalence in the general population: heterogeneity and concerns: Table 1 Nephrology Dialysis Transplantation, 2016, 31, 331-335.	0.7	83
68	Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 271-279.	4.5	107
69	Stage 5-CKD under nephrology care: to dialyze or not to dialyze, that is the question. Journal of Nephrology, 2016, 29, 153-161.	2.0	18
70	Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. American Journal of Kidney Diseases, 2016, 67, 89-97.	1.9	81
71	Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care. PLoS ONE, 2015, 10, e0127071.	2.5	47
72	Epidemiology of CKD Regression in Patients under Nephrology Care. PLoS ONE, 2015, 10, e0140138.	2.5	27

#	Article	IF	CITATIONS
73	Interplay of Vitamin D, Erythropoiesis, and the Renin-Angiotensin System. BioMed Research International, 2015, 2015, 1-11.	1.9	77
74	Extraskeletal Functions of Vitamin D. BioMed Research International, 2015, 2015, 1-2.	1.9	11
75	Reassessment of Ambulatory Blood Pressure Improves Renal Risk Stratification in Nondialysis Chronic Kidney Disease. Hypertension, 2015, 66, 557-562.	2.7	10
76	Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008–12 National Health Examination Survey. Nephrology Dialysis Transplantation, 2015, 30, 806-814.	0.7	82
77	Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 756-762.	2.6	21
78	Very low-protein diet plus ketoacids in chronic kidney disease and risk of death during end-stage renal disease: a historical cohort controlled study. Nephrology Dialysis Transplantation, 2015, 30, 71-77.	0.7	43
79	Nephroprotection with saxagliptin. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2015, 32, .	0.3	1
80	Risk of ESRD and Death in Patients with CKD Not Referred to a Nephrologist. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1586-1593.	4.5	65
81	Responsiveness to Erythropoiesis-Stimulating Agents in Chronic Kidney Disease: Does Geography Matter?. Drugs, 2014, 74, 159-168.	10.9	15
82	Interaction between phosphorus and parathyroid hormone in non-dialysis CKD patients under nephrology care. Journal of Nephrology, 2014, 27, 57-63.	2.0	8
83	Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter Prospective Cohort Study. American Journal of Kidney Diseases, 2014, 64, 744-752.	1.9	96
84	Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes. American Journal of Kidney Diseases, 2014, 64, 16-24.	1.9	132
85	Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrology Dialysis Transplantation, 2013, 28, 1672-1679.	0.7	118
86	Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrology Dialysis Transplantation, 2013, 28, 3035-3045.	0.7	65
87	Prevalence and Prognostic Role of Resistant Hypertension in Chronic Kidney Disease Patients. Journal of the American College of Cardiology, 2013, 61, 2461-2467.	2.8	139
88	Resistant Hypertension in Nondialysis Chronic Kidney Disease. International Journal of Hypertension, 2013, 2013, 1-8.	1.3	24
89	The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. Kidney International, 2012, 82, 482-488.	5.2	75
90	High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study. Nephrology Dialysis Transplantation, 2012, 27, 2269-2274.	0.7	60

#	Article	IF	Citations
91	Prognosis of CKD Patients Receiving Outpatient Nephrology Care in Italy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2421-2428.	4.5	88
92	Burden of Resistant Hypertension in Hypertensive Patients with Non-Dialysis Chronic Kidney Disease. Kidney and Blood Pressure Research, 2011, 34, 58-67.	2.0	38
93	Prognostic Role of Ambulatory Blood Pressure Measurement in Patients With Nondialysis Chronic Kidney Disease. Archives of Internal Medicine, 2011, 171, 1090-8.	3.8	256
94	Hypertension management in chronic kidney disease: translating guidelines into daily practice. Journal of Nephrology, 2011, 24, 733-741.	2.0	5
95	Conversion of Darbepoetin to Low Doses of CERA Maintains Hemoglobin Levels in Non-Dialysis Chronic Kidney Disease Patients. Blood Purification, 2010, 30, 186-194.	1.8	28
96	Anaemia Management in Non-Dialysis Chronic Kidney Disease: Flexibility of Target to Target Stability?. Nephron Clinical Practice, 2010, 114, c236-c241.	2.3	7
97	Prevalence and Prognosis of Mild Anemia in Non-Dialysis Chronic Kidney Disease: A Prospective Cohort Study in Outpatient Renal Clinics. American Journal of Nephrology, 2010, 32, 533-540.	3.1	28
98	Epoetin Therapy and Hemoglobin Level Variability in Nondialysis Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 552-559.	4.5	18
99	Restriction of Dietary Protein and Long-term Outcomes in Patients With CKD. American Journal of Kidney Diseases, 2009, 54, 183-184.	1.9	8
100	Detection and Awareness of Moderate to Advanced CKD by Primary Care Practitioners: A Cross-sectional Study From Italy. American Journal of Kidney Diseases, 2008, 52, 444-453.	1.9	98
101	Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression. American Journal of Kidney Diseases, 2008, 52, 475-485.	1.9	76
102	Waist:hip ratio is a better predictor of cardiovascular risk than BMI in patients with moderate CKD. Nature Clinical Practice Nephrology, 2008, 4, 592-593.	2.0	6
103	Prevalence and clinical correlates of white coat hypertension in chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 22, 2217-2223.	0.7	47
104	Stability of Target Hemoglobin Levels during the First Year of Epoetin Treatment in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 938-946.	4.5	25
105	Effects of age on hypertensive status in patients with chronic kidney disease. Journal of Hypertension, 2007, 25, 2325-2333.	0.5	17
106	Changing the Timing of Antihypertensive Therapy to Reduce Nocturnal Blood Pressure in CKD: An 8-Week Uncontrolled Trial. American Journal of Kidney Diseases, 2007, 50, 908-917.	1.9	120
107	Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. Journal of Hypertension, 2006, 24, 1655-1661.	0.5	59
108	Early Changes in Bioelectrical Estimates of Body Composition in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 1481-1487.	6.1	109

#	Article	IF	CITATIONS
109	Management of Hypertension in Patients With CKD: Differences Between Primary and Tertiary Care Settings. American Journal of Kidney Diseases, 2005, 46, 18-25.	1.9	42
110	Italian Audit on Therapy of Hypertension in Chronic Kidney Disease: The TABLE-CKD Study. Seminars in Nephrology, 2005, 25, 425-430.	1.6	19
111	Achievement of target blood pressure levels in chronic kidney disease: a salty question?. American Journal of Kidney Diseases, 2004, 43, 782-795.	1.9	91
112	Maximal suppression of renin-angiotensin system in patients with refractory proteinuria. American Journal of Hypertension, 2003, 16, A1.	2.0	0
113	Postdialytic Rebound of Serum Phosphorus. Journal of the American Society of Nephrology: JASN, 2002, 13, 1046-1054.	6.1	94
114	Effect of Dialysate Sodium Concentration on Interdialytic Increase of Potassium. Journal of the American Society of Nephrology: JASN, 2000, 11, 2337-2343.	6.1	53
115	Salt Intake and Renal Outcome in Patients with Progressive Renal Disease. Mineral and Electrolyte Metabolism, 1998, 24, 296-301.	1.1	135
116	Short-term effects of low protein-normal sodium diet on renal function in chronic renal failure. Kidney International, 1994, 45, 852-860.	5.2	12
117	Reply to Mocanu CA et al. American Journal of Clinical Nutrition, 0, , .	4.7	1